EPX-100 Emerging Drug Insight

“EPX-100 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about EPX-100 for Developmental and Epileptic Encephalopathy in the 7MM. A detailed picture of the EPX-100 for Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the EPX-100 for Developmental and Epileptic Encephalopathy. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EPX-100 market forecast, analysis for Developmental and Epileptic Encephalopathy in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Developmental and Epileptic Encephalopathy.

Drug Summary

EPX-100 is a repurposed antihistamine that was used in the past to treat itchiness. The medication can suppress seizures via modulation of serotonin (5HT) signaling pathways, which is different from its anti-histaminic properties. EPX-100 was a powerful suppressor of spontaneous convulsive behavior and electrographic seizures in zebrafish disease models for Dravet syndrome. EPX-100’s antiepileptic action is not through a histaminergic mechanism of action but acts via modulation of serotonin (5HT) signaling pathways.

Currently, the drug is in Phase II trial (NCT04462770) as a single pivotal study to compare the efficacy of EPX-100 against placebo as adjunctive therapy in 60 patients with Dravet Syndrome. Apart from this, EPX-100 is also evaluated as a single pivotal study in the Phase II trial (NCT05066217) as adjunctive therapy in children with LGS.

As per the company, the topline results of EPX-100 for Dravet syndrome are expected in the first quarter of 2023, the complete enrollment was expected in the second quarter of 2022. Moreover, EPX-100 is CTA approved by MHRA, the UK for Dravet syndrome. Similarly, the topline results of EPX-100 for LGS are expected in the second quarter of 2023, and the complete enrollment is expected in the third quarter of 2022.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the EPX-100 description, mechanism of action, dosage and administration, research and development activities in Developmental and Epileptic Encephalopathy.
•  Elaborated details on EPX-100 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the EPX-100 research and development activity in Developmental and Epileptic Encephalopathy details across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around EPX-100.
•  The report contains forecasted sales of EPX-100 for Developmental and Epileptic Encephalopathy till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for Developmental and Epileptic Encephalopathy.
•  The report also features the SWOT analysis with analyst views for EPX-100 in Developmental and Epileptic Encephalopathy.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EPX-100 Analytical Perspective by DelveInsight

• In-depth EPX-100 Market Assessment

This report provides a detailed market assessment of EPX-100 in Developmental and Epileptic Encephalopathy in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• EPX-100 Clinical Assessment

The report provides the clinical trials information of EPX-100 for Developmental and Epileptic Encephalopathy covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for Developmental and Epileptic Encephalopathy is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EPX-100 dominance.
•  Other emerging products for Developmental and Epileptic Encephalopathy are expected to give tough market competition to EPX-100 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EPX-100 in Developmental and Epileptic Encephalopathy.
•  Our in-depth analysis of the forecasted sales data of EPX-100 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EPX-100 in Developmental and Epileptic Encephalopathy.

Key Questions

•  What is the product type, route of administration and mechanism of action of EPX-100?
•  What is the clinical trial status of the study related to EPX-100 in Developmental and Epileptic Encephalopathy and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EPX-100 development?
•  What are the key designations that have been granted to EPX-100 for Developmental and Epileptic Encephalopathy?
•  What is the forecasted market scenario of EPX-100 for Developmental and Epileptic Encephalopathy?
•  What are the forecasted sales of EPX-100 in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available in Developmental and Epileptic Encephalopathy and how are they giving competition to EPX-100 for Developmental and Epileptic Encephalopathy?
•  Which are the late-stage emerging therapies under development for the treatment of Developmental and Epileptic Encephalopathy?